Zealand Pharma A/S ZEAL
Day range unavailable
52-week range unavailable
- Market cap
- 814.14M
- Revenue (ttm)
- 293.77M
- Shares out
- 46.12M
- Forward P/E
- -6.49
- Beta
- 1.34
- Analysts
- Buy
- Price target
- 32.30 (+83.6%)
- Earnings date
- Nov 10, 2022
Key statistics
- Enterprise value
- 434.86M
- PEG ratio
- 0.00
- Price / sales
- 2.77
- Price / book
- 1.61
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -22.40%
- Free cash flow
- -505.17M
- Total cash
- 864.44M
- Total debt
- 485.42M
- Return on equity
- -115.45%
- Short % of float
- 0.00%
- 50-day average
- 17.73
- 200-day average
- 15.57
Analyst view
Consensus: buy
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 10, 2022
Expected Nov 10, 2022. Consensus EPS estimate -0.71.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 10, 2022 | Sep 1, 2022 | -0.83 | — | — | — |
| Aug 11, 2022 | Jun 1, 2022 | -1.53 | — | — | — |
| May 12, 2022 | Mar 1, 2022 | -1.01 | — | — | — |
| Mar 10, 2022 | Dec 1, 2021 | -1.07 | — | — | — |
| Nov 11, 2021 | Sep 1, 2021 | -1.13 | — | — | — |
| Aug 12, 2021 | Jun 1, 2021 | -0.93 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 13, 2022 | Needham | main | — | Buy |
| Nov 13, 2020 | Morgan Stanley | main | — | Overweight |
| Oct 13, 2020 | Morgan Stanley | main | — | Overweight |
| Aug 14, 2020 | Morgan Stanley | main | — | Overweight |
| Apr 15, 2020 | Morgan Stanley | main | — | Overweight |
| Mar 31, 2020 | Morgan Stanley | main | — | Overweight |
About Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Denmark
- Website
- zealandpharma.com
News
Zealand Pharma Announces Financial Results for the First Nine Months of 2026 
Zealand Pharma to participate in the Jefferies Global Healthcare Conference 
Zealand Pharma announces Boehringer Ingelheim's survodutide is the first glucagon/GLP-1 dual agonist to demonstrate a favorable cardiovascular safety profile in global Phase 3 SYNCHRONIZE-CVOT trial with significant cardiometabolic benefits 
Zealand Pharma conference call on Nov 12 at 2pm CET (8am ET) to present third quarter 2026 financial results 
Generate Biomedicines To Receive $30M Upfront, Up To $1.2B In Milestones And Tiered Royalties Under Zealand Pharma Collaboration 
Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday 
Why Twin Vee Powercats Is Trading Higher By Around 90%, Here Are 84 Stocks Moving In Friday's Mid-Day Session 
Stocks That Hit 52-Week Lows On Monday 
Earnings Scheduled For May 12, 2022 
Earnings Scheduled For March 10, 2022
Your note
Sign in to keep a note on ZEAL — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Goldman Sachs Group Inc | 1.08% | 500,916 | 8.81M | Jun 29, 2022 |
| Farallon Capital Management Llc | 1.07% | 496,890 | 8.74M | Mar 30, 2022 |
| Bank of America Corporation | 0.47% | 220,523 | 3.88M | Jun 29, 2022 |
| AWM Investment Company, Inc. | 0.11% | 48,957 | 861.15K | Jun 29, 2022 |
| Jane Street Group, LLC | 0.05% | 23,976 | 421.74K | Jun 29, 2022 |
| Morgan Stanley | 0.01% | 6,705 | 117.94K | Jun 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) International Discovery Fund | 2.85% | 1,326,807 | 23.34M | Mar 30, 2022 |
| iShares Core MSCI EAFE ETF | 0.43% | 200,193 | 3.52M | Aug 30, 2022 |
| iShares MSCI EAFE Small Cap ETF | 0.32% | 148,974 | 2.62M | Aug 30, 2022 |
| iShares Core MSCI Total International Stock ETF | 0.14% | 66,909 | 1.18M | Aug 30, 2022 |
| iShares MSCI Denmark ETF | 0.13% | 59,501 | 1.05M | Aug 30, 2022 |
| Hartford Healthcare Fund | 0.12% | 57,750 | 1.02M | Jan 30, 2022 |